Immune-Correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-C secretion with increased HIV-1 infection risk: A cohort- Based modeling study

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Huang, Yunda ^a   Duerr, Ann ^a,b   Frahm, Nicole ^a,b   Zhang, Lily ^a   Moodie, Zoe ^a   De Rosa, Steve ^a,b   Mcelrath, M Juliana ^a,b   Gilbert, Peter B ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; PLACEBO; GAG PROTEIN; NEF PROTEIN; POL PROTEIN; RECOMBINANT PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION RISK; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; COHORT ANALYSIS; FOLLOW UP; GENETICS; HIV INFECTIONS; IMMUNOASSAY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; RISK; SECRETION (PROCESS);

AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FOLLOW-UP STUDIES; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOASSAY; INTERFERON-GAMMA; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROPORTIONAL HAZARDS MODELS; RECOMBINANT PROTEINS; RISK;

EID: 84934343721     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108631     Document Type: Article

References (20)

1. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
2. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, et al. (2012) Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 206: 258-266.
3. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV- 1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. The Lancet 372: 1894-1905.
4. Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, et al. (2012) Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J Virol 86: 2239-2250.
5. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, et al. (2012) Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 122: 359-367.
6. Fellay J, Frahm N, Shianna KV, Cirulli ET, Casimiro DR, et al. (2011) Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial. J Infect Dis 203: 773-779.
7. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, et al. (2011) Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: A double-blind, randomised, placebo-controlled test-ofconcept phase 2b study. Lancet Infect Dis 11: 507-515.
8. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, et al. (2013) Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369: 2083-2092.
9. Dubey S, Clair J, Fu TM, Guan L, Long R, et al. (2007) Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr 45: 20-27.
10. Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, et al. (2007) Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 323: 39-54.
11. Grambsch PM, Therneau TM (1994) Proportional Hazards Tests and Diagnostics Based on Weighted Residuals. Biometrika 81: 515-526.
12. Therneau TM, Li H (1999) Computing the Cox model for case cohort designs. Lifetime Data Anal 5: 99-112.
13. Borgan O, Langholz B, Samuelsen SO, Goldstein L, Pogoda J (2000) Exposure stratified case-cohort designs. Lifetime Data Anal 6: 39-58.
14. Huang Y, Huang Y, Moodie Z, Li S, Self S (2012) Comparing and combining data across multiple sources via integration of paired-sample data to correct for measurement error. Stat Med 31: 3748-3759.
15. Tenbusch M, Ignatius R, Temchura V, Nabi G, Tippler B, et al. (2012) Risk of immunodeficiency virus infection may increase with vaccine-induced immune response. J Virol 86: 10533-10539.
16. Jones NG, DeCamp A, Gilbert P, Peterson ML, Gurwith M, et al. (2009) AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in highrisk, HIV-negative volunteers who subsequently acquire HIV infection. Vaccine 27: 1136-1140.
17. Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, et al. (2012) Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis 206: 993-1001.
18. Naranbhai V, Altfeld M, Karim QA, Ndung'u T, Karim SSA, et al. (2012) Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial. AIDS 26: 1745-1753.
19. Naranbhai V, Samsunder N, Sandler NG, Roque A, Abdool Karim Q, et al. (2013) Neither microbial translocation nor TLR responsiveness are likely explanations for preexisting immune activation in women who subsequently acquired HIV in CAPRISA 004. J Acquir Immune Defic Syndr 63: 294-298.
20. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286.